SAN FRANCISCO— The orally administered androgen receptor blocker enzalutamide significantly extended both overall survival and radiographically determined progression-free survival in men whose metast
SAN FRANCISCO— The orally administered androgen receptor blocker enzalutamide significantly extended both overall survival and radiographically determined progression-free survival in men whose metastatic castration-resistant prostate cancer was asymptomatic or mildly symptomatic and had not been treated with chemotherapy in the phase III PREVAIL study. Dr Tomasz Beer MD, FACP, from Oregon Health & Science University in Portland, USA, presented his group’s findings to the 2014 ASCO Genitourinary Cancers Symposium from 1717 patients randomised to treatment with enzalutamide or placebo. Overall survival was extended by over two months to a median of 32.4 months while progression free survival went up from four to 14 months with the active drug. He discussed the clinical implications with AudioMedica.com.
CONTACT:
Dr. Tomasz Beer MD, FACP
Oregon Health & Science University
Hematology and Medical Oncology,
Portland
3181 S.W. Sam Jackson Park Rd.
Oregon 97239-3098
SOURCE:
Abstract number: LBA1^
LINK:
Web link: http://www.asco.org/sites/www.asco.org/files/gu14_lba1.pdf
Tags
Related Episodes
Responses to enzalutamide after prior abiraterone therapy in men with castration-resistant metastatic prostate cancer
SAN FRANCISCO— Four out of ten patients whose metastatic castration resistant prostate cancer had already been treated with abiraterone responded to further ‘new generation’ androgen depri
Jefferson DeKloe BSc: Big US Study Confirms Benefit of HPV Vaccination for Boys as Well as Girls
The cancer prevention benefit of vaccination against the human papilloma virus cancer prevent are slowly accruing thanks to European, American and other population-based studies. I’m Peter Goodwin wi
Luis Paz-Ares MD PhD: Longer Survival Among Patients with Extensive Stage Small Cell Lung Cancer Treated with Lurbinectedin Maintenance —ASCO 2025
Luis G Paz-Ares MD PhD discdusses the addition of lurbinectedin as maintenance therapy for extensive stage small cell lung cancer (SCLC)